192 related articles for article (PubMed ID: 18674407)
1. Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population.
Wu E; Greenberg PE; Yang E; Yu A; Erder MH
Curr Med Res Opin; 2008 Sep; 24(9):2587-95. PubMed ID: 18674407
[TBL] [Abstract][Full Text] [Related]
2. Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants.
Wu E; Greenberg P; Yang E; Yu A; Ben-Hamadi R; Erder MH
Curr Med Res Opin; 2008 Oct; 24(10):2805-13. PubMed ID: 18755054
[TBL] [Abstract][Full Text] [Related]
3. Treatment persistence & health care costs of adult MDD patients treated with escitalopram vs. citalopram in a medicaid population.
Wu EQ; Ben-Hamadi R; Lu M; Beaulieu N; Yu AP; Erder MH
Manag Care; 2012 Jan; 21(1):49-58. PubMed ID: 22332457
[TBL] [Abstract][Full Text] [Related]
4. Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs.
Wu EQ; Greenberg PE; Yang E; Yu AP; Ben-Hamadi R; Erder MH
J Med Econ; 2009 Jun; 12(2):124-35. PubMed ID: 19566483
[TBL] [Abstract][Full Text] [Related]
5. Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder.
Zhou ZY; Sun S; Chopra P; Zhong Y; Totev T; Signorovitch J
J Med Econ; 2015; 18(11):919-29. PubMed ID: 26121061
[TBL] [Abstract][Full Text] [Related]
6. Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons.
Wu EQ; Ben-Hamadi R; Yu AP; Tang J; Haim Erder M; Bose A
J Med Econ; 2010; 13(2):314-23. PubMed ID: 20504111
[TBL] [Abstract][Full Text] [Related]
7. Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram.
Wu EQ; Greenberg PE; Ben-Hamadi R; Yu AP; Yang EH; Erder MH
Am Health Drug Benefits; 2011 Mar; 4(2):78-87. PubMed ID: 25126340
[TBL] [Abstract][Full Text] [Related]
8. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.
Wu EQ; Yu AP; Lauzon V; Ramakrishnan K; Marynchenko M; Ben-Hamadi R; Blum S; Erder MH
Ann Pharmacother; 2011 Apr; 45(4):441-51. PubMed ID: 21415162
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on the pharmacoeconomics of escitalopram in depression.
Croom KF; Plosker GL
CNS Drugs; 2004; 18(7):469-73. PubMed ID: 15139801
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
Nordström G; Despiegel N; Marteau F; Danchenko N; Maman K
J Med Econ; 2010; 13(3):516-26. PubMed ID: 20698748
[TBL] [Abstract][Full Text] [Related]
11. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria.
Hemels ME; Kasper S; Walter E; Einarson TR
Curr Med Res Opin; 2004 Jun; 20(6):869-78. PubMed ID: 15200745
[TBL] [Abstract][Full Text] [Related]
13. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
Azorin JM; Llorca PM; Despiegel N; Verpillat P
Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
[TBL] [Abstract][Full Text] [Related]
14. Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.
Esposito D; Wahl P; Daniel G; Stoto MA; Erder MH; Croghan TW
Clin Ther; 2009 Mar; 31(3):644-56. PubMed ID: 19393855
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
Fantino B; Moore N; Verdoux H; Auray JP
Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
[TBL] [Abstract][Full Text] [Related]
16. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom.
Wade AG; Toumi I; Hemels ME
Clin Ther; 2005 Apr; 27(4):486-96. PubMed ID: 15922821
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression.
Hemels ME; Kasper S; Walter E; Einarson TR
Ann Pharmacother; 2004 Jun; 38(6):954-60. PubMed ID: 15113989
[TBL] [Abstract][Full Text] [Related]
18. Assessing the comparative-effectiveness of antidepressants commonly prescribed for depression in the US Medicare population.
Kaplan C; Zhang Y
J Ment Health Policy Econ; 2012 Dec; 15(4):171-8. PubMed ID: 23525835
[TBL] [Abstract][Full Text] [Related]
19. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
Waugh J; Goa KL
CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
[TBL] [Abstract][Full Text] [Related]
20. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.
Llorca PM; Fernandez JL
Int J Clin Pract; 2007 Apr; 61(4):702-10. PubMed ID: 17394446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
